Sentences with phrase «apoquel in»

I am very interested in getting feedback from pet parents that have had the opportunity to use Apoquel in their dogs.

IMPORTANT SAFETY INFORMATION: Do not use APOQUEL in dogs less than 12 months of age or those with serious infections.

Not exact matches

Apoquel is a JAK - 1 inhibitor that is especially formulated and duly approved by the FDA for use in the control and management of intense itching in dogs.

As an allergy medication for dogs, Apoquel provides instant relief from itching and may help prevent the development of secondary bacterial infections brought about by the loss of skin integrity inherent in incessant scratching.

«A Blinded Randomized Placebo - controlled Trial of the Efficacy and Safety of the Janus Kinase Inhibitor Oclacitinib (Apoquel ®) in Client - owned Dogs with Atopic Dermatitis» was designed in support of a new drug registration to evaluate the safety and efficacy of AApoquel ®) in Client - owned Dogs with Atopic Dermatitis» was designed in support of a new drug registration to evaluate the safety and efficacy of APOQUELAPOQUEL.

Home / NEWS & MEDIA / pivotal data demonstrating efficacy and safety of apoquel ® published in veterinary dermatology

Missing a dose will lead to some changes in the plasma levels of the active ingredient of Apoquel.

APOQUEL is a targeted new approach to rapidly and safely stop the cycle of itch and inflammation associated with allergic skin disease in dogs.

APOQUEL is the only animal health product approved for both the control of pruritus associated with allergic dermatitis and the control of atopic dermatitis in dogs over 12 months of age.

APOQUEL ® should not be used in dogs less than 12 months of age or in dogs with serious infections.

Eighteen board - certified veterinary dermatologists in the United States enrolled a total of 299 dogs 1 year of age or older to receive APOQUEL or excipient - matched placebo at a dose of 0.4 - 0.6 mg / kg twice - daily for 14 days, and then once - daily at the same dose for up to 112 days.

Recent advancements have been made in the area of antipruritic medications for animals and there are now effective medications with fewer long term side effects such as cyclosporine (Atopica) and oclacitinib (Apoquel).

A blinded, randomized, placebo - controlled trial of the efficacy and safety of the Janus kinase inhibitor oclacitinib (Apoquel ®) in client - owned dogs with atopic dermatitis.

Yes, APOQUEL is safe to be used with other treatments such as vaccines, nonsteroidal anti-inflammatory drugs (NSAIDs), antibiotics, and other allergy medications.4 The use of APOQUEL has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents.

Weekly, bi-monthly or monthly medicated baths, using daily ear washes, Hypoallergenic prescription diet food and treats, medications (Apoquel, Atopica, antibiotics, antifungals, allergy immunotherapy, etc), routine lab work and exams are necessary to keep your pet in their best health to avoid flare ups and addressing any skin issues before they become worse.

APOQUEL is prescribed by your veterinarian to control itch and stop inflammation associated with allergic or atopic dermatitis in dogs 12 months and older.

Gonzales AJ, Bowman JW, Fici GJ, Zhang M, Mann DW, Mitton - Fry M. Oclacitinib (APOQUEL ®) is a novel Janus kinase inhibitor with activity against cytokines involved in allergy.

These occurred in only a small percentage of dogs treated with APOQUEL.

The most common side effects seen in dogs administered APOQUEL were vomiting and diarrhea.

APOQUEL was approved by the U.S. Food and Drug Administration in May 2013 and is the first and only Janus kinase (JAK) inhibitor approved for veterinary use.

APOQUEL should not be used in breeding dogs, or pregnant or lactating dogs.

«APOQUEL is just one example that shows how we are continuing to invest in innovative new approaches that help veterinarians address real - world conditions, such as allergic and atopic dermatitis.»

«Pet owners who complained that their dogs would wake them up in the middle of the night due to intense itch have told me that after treatment with APOQUEL, the household can sleep more peacefully,» Dr. Lewis said.

We are sorry to announce that due to a pharmaceutical backorder, The Drake Center is experiencing a shortage of Apoquel, a new medication recently released on the veterinary market to relieve itching in dogs with allergic skin disease.

A masked, multisite, well - controlled study of 436 dogs conducted at 26 veterinary clinics in the US evaluated the effectiveness and safety of APOQUEL, dosed orally twice daily (BID) at 0.4 to 0.6 mg / kg for the control of pruritus associated with allergic dermatitis, including flea allergy, food allergy, contact allergy and atopic dermatitis

Apoquel works regardless of the type of allergy and can start to relive the itch in as little as four hours.

In a trial of dogs with atopic dermatitis, dogs treated with APOQUEL experienced a significant and long - term reduction in itch and inflammation at day 28 of the studIn a trial of dogs with atopic dermatitis, dogs treated with APOQUEL experienced a significant and long - term reduction in itch and inflammation at day 28 of the studin itch and inflammation at day 28 of the study.

The first drug in its class to be approved for veterinary use, Apoquel is specifically designed to address the source of the itch, providing fast - acting relief and minimal side effects.

With APOQUEL, veterinarians now have a first - in - class treatment choice that targets the itch of allergic skin conditions at its source.

In a trial of dogs with allergic dermatitis, APOQUEL produced rapid onset of efficacy within 24 hours.

In cases where APOQUEL treatment was continued, success rates remained constant through day 112.

APOQUEL has not been evaluated in combination with systemic immunosuppressive agents such as glucocorticoids or cyclosporine.

In addition, Apoquel can be used for both acute and chronic conditions, which is especially wonderful for those dogs needing long - term itch control with minimal side effects.

Florham Park, N.J. — August 13, 2013 — Results of a new pivotal study show that APOQUEL ® (oclacitinib tablet) provides effective and safe control of pruritus associated with allergic dermatitis in dogs with a rapid onset of efficacy within 24 hours and without the commonly reported side effects of steroids.

The most common side effects observed in dogs treated with APOQUEL were vomiting (2.3 % in APOQUEL - treated dogs compared to 1.8 % in placebo treated dogs) and diarrhea (2.3 % in APOQUEL - treated dogs compared to 0.9 % in placebo treated dogs).

APOQUEL produced rapid onset of efficacy within 24 hours - within the first day of treatment, pruritus scores were reduced by at least 2 cm on a 10 cm VAS scale in 44 % of the APOQUEL - treated dogs compared with 19 % of the placebo - treated dogs.

About the Study The study, «Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis,» was conducted as a double - masked, placebo - controlled clinical trial aimed to evaluate the safety and efficacy of APOQUEL compared with placebo.

APOQUEL is the only animal health product approved for the control of pruritus associated with allergic dermatitis and the control of atopic dermatitis in dogs over 12 months of age.

In previously reported laboratory studies, APOQUEL inhibited IL -31-induced pruritus in dogs faster than oral prednisolone and dexamethasonIn previously reported laboratory studies, APOQUEL inhibited IL -31-induced pruritus in dogs faster than oral prednisolone and dexamethasonin dogs faster than oral prednisolone and dexamethasone.

Holistic veterinarian Deva Khalsa VMD describes how these drugs work in her articles on Atopica and Apoquel.

In both studies, dogs that remained on APOQUEL beyond one week experienced continuous improvement throughout the course of the study.

In a trial of dogs with allergic dermatitis, treatment success, as defined by owner - assessed decrease in pruritus, occurred in 67 percent of dogs treated with APOQUEL vs. 29 percent of dogs treated with placebo after one week of treatmenIn a trial of dogs with allergic dermatitis, treatment success, as defined by owner - assessed decrease in pruritus, occurred in 67 percent of dogs treated with APOQUEL vs. 29 percent of dogs treated with placebo after one week of treatmenin pruritus, occurred in 67 percent of dogs treated with APOQUEL vs. 29 percent of dogs treated with placebo after one week of treatmenin 67 percent of dogs treated with APOQUEL vs. 29 percent of dogs treated with placebo after one week of treatment.

In a clinical trial of dogs with atopic dermatitis, treatment success for pruritus occurred in a significantly greater percentage of the dogs treated with APOQUEL (66 percent) vs. (4 percent) of dogs treated with placebo (p < 0.0001In a clinical trial of dogs with atopic dermatitis, treatment success for pruritus occurred in a significantly greater percentage of the dogs treated with APOQUEL (66 percent) vs. (4 percent) of dogs treated with placebo (p < 0.0001in a significantly greater percentage of the dogs treated with APOQUEL (66 percent) vs. (4 percent) of dogs treated with placebo (p < 0.0001).

The frequency and type of adverse events were similar between APOQUEL - and placebo - treated dogs in short - term trials.

«The good news is that Zoetis» revolutionary treatment for allergic itch, Apoquel, can help your dog in as little as four hours.

Apoquel is used to treat and control itching and inflammation in dogs resulting from a variety of causes, including flea allergy, food allergy, contact allergy and atopic dermatitis.

The use of Apoquel has not been evaluated in combination with glucocorticoids, cyclosporine, or other systemic immunosuppressive agents.

Apoquel is not for use in breeding dogs, or pregnant or lactating bitches.

«Efficacy and safety of oclacitinib (APOQUEL) compared to cyclosporine (Atopica, Novartis Animal Health) for the control of atopic dermatitis in client - owned dogs»

«Efficacy and safety of oclacitinib (APOQUEL) compared to prednisolone for the control of pruritus and clinical signs associated with allergic dermatitis in client - owned dogs»